FDC Ltd
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
FDC Ltd's management has indicated a stable revenue growth trajectory, consistent with historical performance, which is supported by the expanding Indian pharmaceutical sector. The company's focus on innovative products and biosimilars aligns with industry trends that favor higher-margin offerings, enhancing its competitive position. Additionally, improving pricing power within the sector is expected to bolster margins, contributing to an overall positive earnings outlook. Vista's forecast reflects these developments, projecting an improvement in profitability as margins expand, despite potential headwinds from rising input costs. The balance sheet remains conservatively financed, with low leverage supporting financial stability. While the macro environment in India is conducive to growth, with favorable liquidity conditions and contained inflation, the potential for margin pressures, particularly in the U.S. market, warrants caution. Over the next 12-24 months, FDC's ability to capitalize on export opportunities and maintain its focus on innovative therapies will be critical. Investors should monitor the competitive landscape and regulatory developments, as these factors could significantly influence FDC's market share and long-term growth prospects
Why We Like This Stock
Things To Watch Out For
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,943 | 2,108 | 2,171 | 2,147 | 2,107 |
| Profit Before Tax (Cr.) | 375 | 347 | 396 | 311 | 325 |
| PBT Margin | 19.3% | 16.5% | 1824.0% | 14.5% | 15.4% |
| Net Profit (Cr.) | 292 | 264 | 304 | 239 | 250 |
| Earnings Per Share | 17.9 | 16.2 | 18.7 | 14.7 | 15.3 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynaecology, dermatology, and analgesics in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured ORS powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients. The company sells its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Vitcofol, Ziglim, Ziglim-M,Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Electral, and Enerzal brands. It also exports its products to approximately 50 countries. FDC Limited was founded in 1936 and is based in Mumbai, India.